Author

K. Wohlan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:development & morphogenesis· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

A. G. Guzman· 1 shared A. G. Martell· 1 shared A. Ganser· 1 shared A. Nussenzweig· 1 shared A. Tovy· 1 shared B. B. de Vries· 1 shared C. Coarfa· 1 shared C.-w. Chen· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. G. Guzman

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

SOD1 is a synthetic lethal target in PPM1D-mutant leukemia cells

L. Zhang, J. I. Hsu, E. D. Braekeleer, C.-w. Chen, T. D. Patel, A. G. Martell, A. G. Guzman, K. Wohlan, S. M. Waldvogel, H. Urya, A. Tovy, E. Callen, R. L. Murdaugh, R. U. Richard, S. Jansen, , M. A. Goodell

This study identifies SOD1 as a synthetic lethal target in PPM1D-mutant leukemia cells through CRISPR/Cas9 screening, revealing a dysregulated redox landscape and potential therapeutic strategy.

bioRxiv · Aug 31, 2023Cancer Biology

Targeted anti-BCR-ABL+ ALL therapy may benefit the heart

H. Kirchhoff, M. Ricke-Hoch, K. Wohlan, S. Pietzsch, U. Karsli, S. Erschow, R. Zweigerdt, A. Ganser, M. Eder, M. Scherr, D. Hilfiker-Kleiner

This paper shows that targeted therapies for BCR-ABL+ ALL can cause heart damage, but some treatments like dasatinib and venetoclax can reverse cardiac defects while others cannot.

bioRxiv · Jun 4, 2021 · PreprintCancer Biology